Drug news
Animas Vibe Insulin Pump system approved by FDA for managing diabetes in patients 2-17- Animas Corporation
Animas Corporation announced that FDA has approved the use of the Animas Vibe Insulin Pump and Continuous Glucose Monitoring (CGM) System for the management of diabetes in children and adolescents, ages two to 17. The System allows patients and their caregivers to view glucose data and administer insulin right from the pump, making it easy to fine-tune insulin delivery to help manage their diabetes.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.